Kestra Advisory Services LLC lifted its position in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 417.1% during the third quarter, Holdings Channel.com reports. The firm owned 44,231 shares of the company’s stock after buying an additional 35,678 shares during the quarter. Kestra Advisory Services LLC’s holdings in Elevance Health were worth $17,198,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also added to or reduced their stakes in the company. Claro Advisors Inc. lifted its holdings in shares of Elevance Health by 39.2% during the third quarter. Claro Advisors Inc. now owns 1,267 shares of the company’s stock worth $492,000 after buying an additional 357 shares in the last quarter. QTR Family Wealth LLC acquired a new position in shares of Elevance Health in the third quarter valued at about $319,000. Capstone Wealth Management LLC acquired a new position in shares of Elevance Health in the third quarter valued at about $237,000. Chicago Partners Investment Group LLC increased its position in Elevance Health by 119.9% during the third quarter. Chicago Partners Investment Group LLC now owns 5,377 shares of the company’s stock worth $2,366,000 after acquiring an additional 2,932 shares during the period. Finally, Compass Financial Management LLC increased its position in Elevance Health by 15.6% during the third quarter. Compass Financial Management LLC now owns 349 shares of the company’s stock worth $136,000 after acquiring an additional 47 shares during the period. 89.24% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
ELV has been the subject of several analyst reports. Truist Financial lifted their price objective on shares of Elevance Health from $450.00 to $475.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $451.00 target price on shares of Elevance Health in a report on Friday, October 23rd. Wells Fargo & Company raised their target price on shares of Elevance Health from $473.00 to $492.00 and gave the stock an “overweight” rating in a report on Tuesday, October 27th. Mizuho set a $490.00 price target on shares of Elevance Health in a research report on Friday, October 23rd. Finally, UBS Group boosted their price target on Elevance Health from $460.00 to $523.00 and gave the company a “buy” rating in a research note on Thursday, October 22nd. Fifteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, Elevance Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $456.48.
View Our Latest Report on Elevance Health
Insiders Place Their Bets
In other news, EVP Ratnakar Lavu sold 1,300 shares of Elevance Health stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $440.00, for a total transaction of $572,000.00. Following the sale, the executive vice president directly owned 14,849 shares of the company’s stock, valued at approximately $6,533,560. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Mark Kaye sold 10,584 shares of Elevance Health stock in a transaction dated Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total value of $4,658,335.92. Following the sale, the chief financial officer directly owned 19,919 shares in the company, valued at $8,766,949.47. The trade was a 34.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.34% of the stock is currently owned by corporate insiders.
Key Stories Impacting Elevance Health
Here are the key news stories impacting Elevance Health this week:
- Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $29.02 from $27.06, and lifted forecasts for Q1 2027 and Q1 2028 to $11.73 and $12.61, respectively. An additional analyst also raised its Q2 EPS estimate, though the report did not provide the revised figure. Q2 EPS Estimate for Elevance Health Lifted by Analyst
- Neutral Sentiment: EVP Ratnakar Lavu sold 1,300 shares for $572,000, an 8.05% reduction in his holdings. He still directly owned 14,849 shares after the transaction, making the sale a limited insider-sentiment signal. SEC insider transaction filing
- Neutral Sentiment: A separate article considers what would need to be true for Elevance to be an attractive stock purchase, but the supplied article information does not state its conclusion. What Needs To Be True To Buy Elevance Health Stock?
- Negative Sentiment: Zacks Research lowered estimates for Q4 2026 EPS to $2.00 from $2.43, Q3 2027 to $6.01 from $6.70, and Q3 2028 to $7.09 from $7.75. These cuts temper the positive revisions and point to a less favorable outlook for some future quarters.
Elevance Health Trading Up 0.1%
ELV opened at $426.17 on Monday. Elevance Health, Inc. has a twelve month low of $274.84 and a twelve month high of $450.69. The company has a 50-day simple moving average of $412.92 and a 200 day simple moving average of $373.58. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $92.08 billion, a price-to-earnings ratio of 18.17, a P/E/G ratio of 2.03 and a beta of 0.63.
Elevance Health (NYSE:ELV – Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.71 by $2.28. The firm had revenue of $50.44 billion for the quarter, compared to the consensus estimate of $49.28 billion. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The business’s revenue for the quarter was up .7% on a year-over-year basis. During the same period in the prior year, the company posted $6.03 earnings per share. Analysts predict that Elevance Health, Inc. will post 29.15 EPS for the current fiscal year.
Elevance Health Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be given a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a yield of 1.6%. The ex-dividend date is Friday, December 4th. Elevance Health’s payout ratio is currently 29.34%.
Elevance Health Company Profile
Elevance Health, Inc is a U.S. health benefits and services company. Formerly known as Anthem, Inc, it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans.
The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.
Elevance Health operates primarily in the United States, with health plans serving members across multiple states and access to broader provider networks through its Blue Cross Blue Shield affiliations.
Featured Stories
- Five stocks we like better than Elevance Health
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
